Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan-Dec:37:3946320231172881.
doi: 10.1177/03946320231172881.

Report of two sisters with Netherton syndrome successfully treated with dupilumab and review of the literature

Cristina Martin-García  1   2   3 , Elena Godoy  4 , Adelaida Cabrera  1 , Javier Cañueto  4 , Francisco J Muñoz-Bellido  1   2   3 , Jacqueline Perez-Pazos  3 , Ignacio Dávila  1   2   3
Affiliations
Review

Report of two sisters with Netherton syndrome successfully treated with dupilumab and review of the literature

Cristina Martin-García et al. Int J Immunopathol Pharmacol. 2023 Jan-Dec.

Abstract

Different monoclonal antibodies have been used for the treatment of Netherton's syndrome (NS); secukinumab (anti-IL17A), infliximab (anti-TNF-α), ustekinumab (anti p40 subunit of IL-12 and IL-23), omalizumab (anti-IgE), and dupilumab (anti-IL4 and IL13). We report two sisters with severe NS who were treated with omalizumab in one and with secukinumab in the other. In view of the therapeutic failure, treatment with dupilumab was started in both sisters. The data were analyzed 16 weeks after starting treatment with dupilumab. Treatment response was assessed using the Severity Scoring Atopic Dermatitis (SCORAD); Eczema Area and Severity Index (EASI); Pruritus Numeric Rating Scale (NSR); Netherton Area Severity Assessment (NASA) and Dermatology Life Quality Index Ichthyosis. All scores were reduced after 16 weeks of treatment with dupilumab in both patients. She maintains improvement after 18 months and 12 months of treatment, respectively. No severe adverse events were reported. Treatment with dupilumab in two sisters with NS and atopic diseases produced a marked cutaneous improvement after a failed attempt with omalizumab and secukinumab. Further studies are needed to determine which biologic therapy is the most effective in NS.

Keywords: Netherton syndrome; atopic dermatitis; dupilumab; secukinumab.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
(a) Case 1. At baseline vs.16 weeks of treatment with dupilumab (the patient consented to the publication of the photos). (b) Case 2. At baseline vs. 16 weeks of treatment with dupilumab (the patient consented to the publication of the photos).
See this image and copyright information in PMC

References

    1. Chavanas S, Bodemer C, Rochat A, et al. (2000) Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nature genetics 25(2): 141–142. - PubMed
    1. Barbieux C, Bonnet des Claustres M, Fahrner M, et al. (2022) Netherton syndrome subtypes share IL-17/IL-36 signature with distinct IFN-α and allergic responses. The Journal of allergy and clinical immunology 149(4): 1358–1372. - PubMed
    1. Akiyama M. (2022) Understanding immune profiles in ichthyosis may lead to novel therapeutic targets. The Journal of allergy and clinical immunology 149(4): 1210–1212. - PubMed
    1. Eichenfield LF, Tom WL, Chamlin SL, et al. (2014) Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. Journal of the American Academy of Dermatology 70(2): 338–351. - PMC - PubMed
    1. Yan AC, Honig PJ, Ming ME, et al. (2010) The safety and efficacy of pimecrolimus, 1%, cream for the treatment of Netherton syndrome: results from an exploratory study. Archives of dermatology 146(1): 57–62. - PubMed

LinkOut - more resources